Compare Neurocrine Biosciences Inc (NBIX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Tesla, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Tesla, Inc. trades at $366.01 (market cap $1.45T). The key difference: Tesla, Inc. is far larger — about 91.9× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| NBIX | TSLA | |
|---|---|---|
Market Cap | $15.77B | $1.45T |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $489.88 |
52-Week Low | $123.10 | $298.16 |
Enterprise Value | $15.78B | $1.43T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Tesla (TSLA) trades at $368.16, up 3.98% today, amid a bullish technical signal and recent earnings beats despite a Q2 2026 miss. The stock shows elevated valuation multiples with a P/E of 340.89 and P/S of 12.57, while profitability metrics like a 3.67% net income margin reflect competitive pressures. Positive developments include regulatory approval for driver-assistance software in Europe and a potential cheaper EV launch, though cash flow trends indicate heavy investment spending.
The outlook balances innovation potential in autonomy and energy against valuation concerns and execution risks. Near-term catalysts include Q3 2026 earnings, with the consensus price target of $398.38 suggesting modest upside. Key risks are slowing auto demand, high capex, and reliance on future technology adoption to justify current premiums.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
